Abstract: Hepatic siderosis is common in patients with porphyria cutanea tarda (PCT).
Mutations in the hereditary hemochromatosis (hh) gene (HFE) explain the siderosis in approximately 20 percent of cases suggesting that the remaining cases result from additional genetic and environmental factors. Two genes known to modify iron loading in hh are hepcidin (HAMP) and hemojuvelin (HJV). To determine if mutations in or expression of these genes influenced iron overload in PCT, we compared sequences of HAMP and HJV in 96 patients with PCT and 88 HFE C282Y homozygotes with marked hepatic iron overload. We also compared hepatic expression of these and other ironrelated genes in a group of PCT and hh patients. Two intronic polymorphisms in HJV were associated with elevated serum ferritin in HFE C282Y homozygotes. No exonic polymorphisms were identified. Sequencing of HAMP revealed exonic polymorphisms in two patients with PCT: heterozygosity for a G→A transition (G71D substitution) in one and heterozygosity for an A→G transition (K83R substitution) in the other. Hepatic HAMP expression in PCT patients was significantly reduced, regardless of HFE genotype, when compared to hh patients with comparable iron overload. These data indicate that the hepatic siderosis associated with PCT likely results from dysregulated
HAMP.
Introduction: Porphyria cutanea tarda (PCT) is due to a reduction in the activity of the heme biosynthetic enzyme uroporphyrinogen decarboxylase (UROD) in hepatocytes.
Reduced activity of UROD leads to accumulation of the porphyrinogen substrates which are then oxidized to the corresponding porphyrins. Approximately 25% of patients with PCT are heterozygous for UROD mutations and UROD activity and protein are half-normal in all tissues (familial PCT or F-PCT) 1 . Most heterozygotes do not express a disease phenotype. When the disease phenotype is expressed, activity of UROD in hepatocytes is decreased to rate-limiting levels yet UROD protein levels do not change.
The more common form of PCT is not associated with mutations in UROD and UROD activity and UROD protein are normal in all tissues (sporadic PCT or S-PCT). When the disease phenotype is expressed, activity of UROD in hepatocytes is decreased to the same, rate-limiting levels seen in disease-expressing patients with F-PCT. The reduction in specific activity of UROD in both S-PCT and F-PCT is due to the generation of an inhibitor of UROD in hepatocytes 2 . Generation of the inhibitor is highly dependent on the presence of excess hepatic iron 3 . The key role of iron in the pathogenesis of PCT is emphasized by the finding that iron removal by phlebotomy therapy ameliorates all of the clinical manifestations of the disease, including production of the inhibitor.
Approximately 20% of PCT patients are homozygous for the HFE C282Y mutation but the cause of excess hepatic iron in the remaining cases is not known 1, 4, 5 .
Homozygosity for a cysteine to tyrosine change at amino acid position 282 (C282Y) in the HFE protein 6 is found in over 90 percent of patients with hh 7, 8 . Most remaining cases can be explained either by compound heterozygosity for the C282Y mutation and a second HFE mutation resulting in an H63D substitution, or mutations in HAMP, HJV, transferrin receptor 2 (TFR2) and ferroportin (FPN) [9] [10] [11] . [12] [13] [14] [15] [16] . The reason for incomplete penetrance is unknown, but pedigree studies have suggested that other genes modify the phenotype, perhaps by further affecting HAMP expression 13 . Several pedigrees have been identified in which heterozygosity for mutations of HAMP or HJV appeared to magnify the effect of homozygosity for the C282Y mutation of HFE [17] [18] [19] [20] . Furthermore, mouse models clearly indicate that genetic background influences the degree of iron loading associated with mutations in the Hfe gene 21, 22 .
We sought mutations in HJV and HAMP in 96 PCT patients with and without HFE mutations and in 88 hh patients with marked hepatic iron overload. All hh patients were homozygous for the HFE C282Y mutation. We hypothesized that if polymorphisms in HJV, HAMP or both were associated with a highly penetrant phenotype in hh patients, the same alleles might be over represented in patients with PCT who had no HFE mutations. We further hypothesized that hepatic siderosis in PCT might be the result of dysregulation of genes involved in iron metabolism. To investigate this possibility, hepatic expression of HAMP and the iron-related genes FPN, SMAD4, neogenin (NEO), HJV and transferrin receptors 1 and 2 (TFR1, TFR2) were compared between a subset of PCT patients with and without HFE mutations and a control pool of hh patients without PCT and with comparable hepatic iron stores. Statistical analyses: Statistical analyses were performed using SPSS software (Chicago, IL). Independent samples T-tests were performed using a 95% confidence interval. Differences in mean values were considered significant for p values < 0.05.
Correlations were determined using a Spearman two-tailed correlation test.
Correlations were considered significant if p < 0.05. DNA analysis: DNA was prepared from peripheral blood leukocytes using an automated extraction protocol (Autopure, Gentra Systems). DNA extraction and HFE genotyping were performed in the Core Laboratory of the GCRC. Genotyping was done using an allele-specific PCR protocol 25 . Sequencing of HAMP and HJV was performed by PCR amplification and cycle sequencing using Applied Biosystems BigDye
Terminator chemistry. The University of California Santa Cruz (UCSC) genome browser 26 was used to extract positions of proximal promoters and RefSeq exons for HJV (NM_213653) and HAMP (NM_021175). Exons, proximal promoters and genomic sequences conserved in mammals were sequenced using PCR amplification and fluorescent dideoxy DNA sequencing, as previously described was based on a greater than 95% probability of being differentially expressed (P ≤ 0.05) and a fold change of 2 or greater. The resultant false positive discovery rate was estimated in previous work as less than 1% by using semi-quantitative reverse transcriptase-PCR.
Results
Iron phenotypes: HPCSI scores, Tf saturations and serum ferritin concentrations are shown in Table 1A . Among PCT patients for whom DNA was sequenced, 17 (18%)
were HFE C282Y homozygotes, 34 (35%) were HFE C282 heterozygotes and 45 (47%) were wild type homozygotes. Iron parameters in PCT patients were compared by gender and HFE genotype using an Independent-samples T-test (Table 1B) 29 .
Sequence analysis of HJV: HJV has been cloned and mapped to chromosome 1q.
The gene includes a promoter region, 4 exons, 3 introns and a 3' flanking region 30, 31 . We found no promoter or exonic polymorphisms in either study population. Non-coding polymorphisms and associated iron values are presented in Table 2 . In the hh population the C→T transition in intron 3 was in linkage disequilibrium with the T→C transition in the 3' flanking region as the 8 individuals with the C→T transition in intron 3 also had the 3' flanking region T→C transition. The C→T, T→C haplotype was associated with higher serum ferritin values (2677 ± 535 vs. 1361 ± 148, p < 0.004 by Independent-samples T-test) ( Table 2 ). Nine patients with PCT also had the C→T, T→C haplotype, 3 of whom were HFE C282Y homozygotes. One was a 70 year old woman with a serum ferritin value of 957 ng/ml, the second a 64 year old man with a serum ferritin value of 1106 ng/ml and the third, a 5 year old boy with a serum ferritin value of 91 ng/ml (normal value for age 14-80 ng/ml). The mean serum ferritin value in PCT patients who were HFE wild type homozygotes or heterozygotes was 540 ng/ml. Polymorphisms detected and iron measures in the subjects sequenced are summarized in Supplemental data Table 2 .
A G→A transition in the third exon was found in a single patient with PCT (Supplemental data Table 2 ). This transition results in a previously identified G71D amino acid change which affects iron loading when present with mutations in HFE 17, 18 . The PCT patient with this polymorphism was a 54-year-old man whose HFE genotype was wt/wt. He had undergone phlebotomy therapy elsewhere and was iron depleted at the time of our evaluation. An A→G transition in the third exon was also found in a 41-year old man with PCT whose HFE genotype was wt/wt (Supplemental data Table 2 ).
This transition results in a K83R change which does not affect the function of the hepcidin peptide 32 . Iron measures in these two patients did not differ significantly when compared to other PCT patients with the wt/wt HFE genotype (Supplemental data Table   2 ). The HFE genotypes of the 14 PCT patients are shown in Table 3 . Patients 1 through 8 were men and all but one (patient 3) was exposed to hepatitis C, excessive alcohol consumption or both. Patients 9 through 14 were women. All were taking medicinal estrogens and all had histological evidence of hepatic steatosis. HAMP expression in patients with PCT was reduced compared to the reference pool of hh patients (mean = minus 3.2-fold). Reduced values ranged from minus 1.2 to minus 10.3-fold (Table 3) .
Comparison of hepatic gene expression in hh and
Only 3 of the 14 PCT patients did not have reduced values (Table 3) . Patients 1 (HFE C282Y/wt) and 2 (HFE wt/wt) had the greatest reduction in HAMP expression. The next lowest patient (patient 13) was homozygous for the HFE 282Y mutation. These data indicate that reduced HAMP expression in PCT is independent of the HFE genotype.
None of the other examined iron-related genes showed differential expression in the PCT patients in comparison with hh patients or in relation to HFE genotype among PCT patients. A Spearman two-tailed correlation analysis was performed on the expression data and negative correlations were found between HAMP and TFR1 expression (Correlation Coefficient (r)= -0.666, p<0.009) and serum ferritin and TFR1 (Correlation Coefficient (r)= -0.577, p<0.039). There was also a positive correlation between neogenin and SMAD4 (Correlation Coefficient (r)= 0.561, p<0.037).
Comparison of PCT patients with and without hepatitis C: Iron values for 18 HepC
positive PCT patients were compared to 13 PCT patients whose HepC serologies were negative. None of the iron values were different between the groups (Table 4 ). The For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From frequency of homozygosity for the HFE C282Y mutation and alcohol use were similar between the two groups (data not shown).
Discussion:
The hepatic siderosis associated with PCT can be explained by homozygosity for the HFE C282Y mutation in a minority of cases but most often the cause of the iron phenotype is not apparent. Several exonic HJV mutations appear to magnify the iron phenotype in HFE-associated hemochromatosis 19, 20, [33] [34] [35] , but we detected no exonic mutation in either our hh patients or our PCT patients. In the hh group, however, heterozygosity for an HJV allele with an intron 3 C→T transition and a 3' flank T→C transition was found in approximately 10% of subjects and these patients had significantly higher serum ferritin values than those without this HJV allele (Table   2) . Two adult PCT patients homozygous for the HFE C282Y mutation were found to have the intron 3 C→T, 3' flank T→C allele. Their serum ferritin values were higher than PCT patients with hh but without these polymorphisms. The mechanism by which the intron 3 C→T, 3' flank T→C allele affects penetrance of hh is not clear as neither of the two polymorphisms affects a sequence predicted to alter transcription or message stability.
The G71D mutation in HAMP has been associated with abnormal iron values when combined with HFE mutations 18 but our single PCT patient with this mutation had a wild type HFE genotype. Our single PCT patient with the K83R mutation also had a wild type HFE genotype. Both were heterozygous for their respective HAMP mutations.
Peptides containing the G71D and K83R substitutions have been synthesized and Iron is recognized as a potent cofactor in alcohol-induced liver injury 40 Oral estrogen use is an independent risk factor for the development of PCT 44 
.
Estrogens may have a variety of adverse effects on the liver including steatosis and steatohepatitis 45, 46 . Evidence in humans and in animal models of non-alcoholic fatty liver disease suggests that oxidative cellular damage plays an important role in disease pathogenesis [47] [48] [49] [50] . HAMP expression has not been previously studied in women with estrogen-induced hepatic steatosis. Six of the patients included in Table 3 were such women and HAMP expression, compared to control subjects with hh, was reduced in most.
Oxidative stress is a finding associated with all of the risk factors for PCT (hh, HepC, alcohol and oral estrogen use). We propose that oxidative stress down-regulates HAMP expression, leading to increased iron export by enterocytes and macrophages.
The resulting hepatic siderosis is required to generate the URO-D inhibitor responsible for expression of the PCT phenotype 2 . Our data suggest that as hepatic porphyrinogens accumulate and are oxidized to porphyrins, down-regulation of HAMP is accentuated. This view is supported by our finding that HAMP expression in patients with PCT is down-regulated beyond that of hh patients whose HAMP expression is already impaired due to the HFE C282Y mutation 51 . The risk factors for PCT are common yet PCT occurs with a frequency of 1/5,000 1 suggesting that traits affecting response to oxidative stress influence disease susceptibility. 
